Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com
StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Stock Performance Shares of CYCC stock opened at $0.31 on Friday. The firm has a market cap of $3.91 million, a P/E ratio […]
More Stories
Judge Rules Virginia Redistricting Referendum Unconstitutional
By Jill McLaughlin A Virginia judge ruled on April 22 that the state’s redistricting referendum approved by voters a day earlier...
US Land Prices Climb 77 Percent Since Pandemic as Inventory Remains Low: Report
By Mary Prenon Land prices across the United States over the last decade seem to be following the path of...
German Airline Lufthansa to Cut 20,000 Flights to Save Jet Fuel
By Victoria Friedman German airline Lufthansa announced on April 21 that 20,000 short-haul flights would be canceled this summer due...
Duffy Seeking $10 Billion From Congress to Revamp Air Traffic Control System
By Aldgra Fredly U.S. Transportation Secretary Sean Duffy said on April 21 the department requires $10 billion in additional funding...
Iran Attacks 2 Container Ships After Trump Extends Ceasefire
By Tom Ozimek Iranian forces fired on two commercial vessels near the Strait of Hormuz on April 22, UK maritime...
Southern Poverty Law Center Charged With Fraud Over Payments to Informants in Extremist Groups
By Tom Gantert The Southern Poverty Law Center was indicted on federal fraud charges that accused it of illegally raising...